Guillain-Barré Syndrome: Autoimmune Neuropathy Causing Ascending Paralysis

Guillain-Barré Syndrome (GBS) is an acute autoimmune polyradiculoneuropathy triggered by molecular mimicry after infection.

Epidemiology & Triggers

  • Incidence: 1–2/100,000/year; slight male predominance.
  • Preceding infection (1–4 weeks prior): Campylobacter jejuni (30%), CMV, EBV, Mycoplasma, Zika, influenza, SARS-CoV-2.
  • Rare post-vaccination (e.g., 1976 swine flu; COVID vaccines – very rare, benefit outweighs risk).

Clinical Course

  • Ascending weakness: Starts in legs → arms → cranial nerves (facial diplegia common).
  • Areflexia/hyporeflexia early sign.
  • Autonomic instability: BP lability, arrhythmias, ileus, urinary retention.
  • Respiratory failure: 20–30% require mechanical ventilation.
  • Nadir at 2–4 weeks; recovery over months to years.

Diagnosis

  • Clinical + albuminocytologic dissociation (CSF: high protein, normal WBC) – appears week 2.
  • Nerve conduction studies: demyelinating (AIDP) vs. axonal (AMAN/AMSAN) variants.
  • Anti-ganglioside antibodies (GM1, GD1a, GQ1b – Miller Fisher variant).

Treatment

  • IVIG 2 g/kg over 5 days or Plasma exchange (5 exchanges) – equally effective; start within 2 weeks.
  • Supportive: ICU monitoring, DVT prophylaxis, pain management (gabapentin), rehab.

Prognosis

  • 70% full recovery; 15–20% residual weakness; 3–5% mortality (despite treatment).
  • Poor predictors: age >60, severe initial weakness, axonal variant, delayed treatment.

Brain & Nervous System - Related Articles